260
Participants
Start Date
April 30, 2006
Primary Completion Date
February 28, 2007
Study Completion Date
February 28, 2007
Motavizumab, palivizumab
Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
Palivizumab, motavizumab
Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
Motavizumab
Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
Neonatalogy John Hunter Hospital, New Lambton Heights
Department of Paediatrics and Child Health, The Canberra Hospital, Garran
Respiratory Medicine Department, Royal Children's Hospital, Parkville
Peninsula Clinical Research Centre, Kippa-Ring
University of Queensland, Royal Children's Hospital, Herston
Caboolture Clinical Research, Caboolture
Women's and Children's Hospital, North Adelaide
Hospital Clinico de la Universidad de Chile, Independencia
Hospital San Jose, Independencia
Hospital Clinico de la Pontificia Universidad Catolica de Chile, Santiago
Hospital Clinico San Borja Arriaran, Santiago
Hospital Dr Felix Bulnes Cerda, Santiago
Hospital Dr. Sotero del Rio, Santiago
Hospital Padre Hurtado, Santiago
Kidz First, Middlemore Hospital, Otahuhu
Christchurch Women's Hospital, Christchurch
Paediatric Medicine, Dunedin Hospital, Dunedin
Department of Paediatrics, Waikato Hospital, Hamilton
Child Health, Palmerston North Hospital, Palmerston North
Lead Sponsor
MedImmune LLC
INDUSTRY